Paper32749941
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
León-Castillo A and 22 others. J Clin Oncol, 2020. Cited by 686 papers, by iCite.
Cite this record
ConductScience Library. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. Papers, record 32749941. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32749941
- Disease
- endometrial cancer242 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Endometrial Neoplasms | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Chemoradiotherapy, Adjuvant | |
| DNA Mismatch Repair | |
| DNA Polymerase II | |
| DNA-Binding Proteins | |
| Female | |
| Humans | |
| Immunohistochemistry | |
| Middle Aged | |
| Paraffin Embedding | |
| Poly-ADP-Ribose Binding Proteins | |
| Prognosis | |
| Radiotherapy, Adjuvant | |
| Randomized Controlled Trials as Topic | |
| Tumor Suppressor Protein p53 |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 8659 | Cancer Research UK | United Kingdom | PubMed | |
| NIHR-CS-012-009 | Department of Health | United Kingdom | PubMed |
Source PubMed
Trials4
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00411138 | Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer | Results | Yes | ClinicalTrials.gov |
| NCT05179447 | PROfiling Based Endometrial Cancer Adjuvant Therapy | Background | ClinicalTrials.gov | |
| NCT05955079 | Circulating Tumor DNA Study in Patients With Endometrial Cancer | Background | ClinicalTrials.gov | |
| NCT06680791 | Molecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle Factors | Background | ClinicalTrials.gov |
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31846532 | Incorporation of molecular characteristics into endometrial cancer management. | Histopathology | 2020 | https://conductscience.org/library/papers/31846532 | PubMed |
| 2 | 28061006 | Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. | Cancer | 2017 | https://conductscience.org/library/papers/28061006 | PubMed |
| 3 | 27397040 | Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27397040 | PubMed |
| 4 | 31492746 | Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31492746 | PubMed |
| 5 | 31829447 | Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas. | J Pathol | 2020 | https://conductscience.org/library/papers/31829447 | PubMed |
| 6 | 29449189 | Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. | Lancet Oncol | 2018 | https://conductscience.org/library/papers/29449189 | PubMed |
| 7 | 22750048 | Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis. | Exp Mol Pathol | 2013 | https://conductscience.org/library/papers/22750048 | PubMed |
| 8 | 30864976 | Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas. | Am J Surg Pathol | 2019 | https://conductscience.org/library/papers/30864976 | PubMed |
| 9 | 31829441 | p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. | J Pathol | 2020 | https://conductscience.org/library/papers/31829441 | PubMed |
| 10 | 27742654 | Practical guidance for mismatch repair-deficiency testing in endometrial cancer. | Ann Oncol | 2017 | https://conductscience.org/library/papers/27742654 | PubMed |
| 11 | 29584549 | Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29584549 | PubMed |
| 12 | 31682550 | Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/31682550 | PubMed |
| 13 | 31829442 | Interpretation of somatic POLE mutations in endometrial carcinoma. | J Pathol | 2020 | https://conductscience.org/library/papers/31829442 | PubMed |
| 14 | 31103324 | Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. | Gynecol Oncol | 2019 | https://conductscience.org/library/papers/31103324 | PubMed |
| 15 | 24576030 | HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. | Arch Pathol Lab Med | 2014 | https://conductscience.org/library/papers/24576030 | PubMed |
| 16 | 29190319 | Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. | Ann Oncol | 2018 | https://conductscience.org/library/papers/29190319 | PubMed |
| 17 | 31345626 | Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/31345626 | PubMed |
| 18 | 23629444 | Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. | Am J Surg Pathol | 2013 | https://conductscience.org/library/papers/23629444 | PubMed |
| 19 | 29432521 | Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. | Ann Oncol | 2018 | https://conductscience.org/library/papers/29432521 | PubMed |
| 20 | 30995174 | Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30995174 | PubMed |
Cited by401
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 686 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42988877 | Evaluation of the Idylla system for rapid detection of POLE mutations in colorectal and endometrial cancers. | Virchows Arch | 2026 | https://conductscience.org/library/papers/42988877 | PubMed |
| 42959168 | Case Report: Endometrial carcinoma harboring a rare POLE p.T278K variant and dual MSH6 frameshift variants. | Front Oncol | 2026 | https://conductscience.org/library/papers/42959168 | PubMed |
| 42947969 | Spatial lipidomics in gynecologic malignancies: molecular identification, cellular attribution, and mechanistic validation. | Front Mol Biosci | 2026 | https://conductscience.org/library/papers/42947969 | PubMed |
| 42941666 | Beyond Molecular Classification: The Incremental Value of Prognostic Biomarkers in Endometrial Cancer. | J Clin Med | 2026 | https://conductscience.org/library/papers/42941666 | PubMed |
| 42938851 | Integrated Molecular Classification of Endometrial Cancer: Impact on Diagnosis, Prognosis, and Clinical Management-A Systematic Review. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938851 | PubMed |
| 42930168 | Targeted Hotspot Mutation Analysis of KRAS, TP53, and PTEN in Endometrial Cancer Revealed by Next-Generation Sequencing. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42930168 | PubMed |
| 42898997 | Endometrial cancer molecular classification: research advances and clinical application. | Front Oncol | 2026 | https://conductscience.org/library/papers/42898997 | PubMed |
| 42886889 | PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study. | JCO Precis Oncol | 2026 | https://conductscience.org/library/papers/42886889 | PubMed |
| 42883850 | Refining the TCGA Framework: The Pivotal Role of Targeted Next-Generation Sequencing in Resolving Diagnostic Ambiguities in Endometrial Cancer-Systematic Review. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42883850 | PubMed |
| 42882917 | Reclassifying No Specific Molecular Profile Endometrial Cancer: A Narrative Review of Molecular Heterogeneity, Prognostic Refinement, and Clinical Management. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882917 | PubMed |
| 42851344 | Advanced endometrial cancer in the gulf cooperation council: a modified-Delphi consensus on unmet needs, molecular testing, and treatment sequencing. | Front Oncol | 2026 | https://conductscience.org/library/papers/42851344 | PubMed |
| 42848197 | [Combination of radiotherapy and medicinal anticancer therapy with curative intent]. | Radiologie (Heidelb) | 2026 | https://conductscience.org/library/papers/42848197 | PubMed |
| 42812477 | Impact of molecular profiling in patients with endometrial cancer: real world experience from India. | Front Oncol | 2026 | https://conductscience.org/library/papers/42812477 | PubMed |
| 42793688 | Molecular Classification of Endometrial Cancer in the Era of Precision Oncology: Prognostic Significance, Emerging Biomarkers, and Personalized Therapeutic Strategies-A Systematic Review. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42793688 | PubMed |
| 42755952 | Oncologic safety of sentinel lymph node-based nodal de-escalation in apparent uterine-confined endometrial cancer: a multicenter international cohort study. | Front Oncol | 2026 | https://conductscience.org/library/papers/42755952 | PubMed |
| 42738293 | Immunotherapy in Gynecologic Cancers: Current Evidence, Biomarker-Driven Practice, and Future Directions. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738293 | PubMed |
| 42720254 | p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer-relevant paralog interplay. | Mol Oncol | 2026 | https://conductscience.org/library/papers/42720254 | PubMed |
| 42706566 | The evolving role of open abdominal surgery in gynecological malignancies in the era of minimally invasive and precision oncology. | World J Surg Oncol | 2026 | https://conductscience.org/library/papers/42706566 | PubMed |
| 42661600 | Microcystic, elongated, and fragmented (MELF) pattern of myometrial invasion in grade 1-2 endometrioid endometrial carcinoma: clinicopathological associations, molecular profile, and prognostic significance under FIGO 2023 staging. | Front Oncol | 2026 | https://conductscience.org/library/papers/42661600 | PubMed |
| 42658373 | Current Treatment Options Guided by Molecular Classification in Endometrial Cancer. | Curr Treat Options Oncol | 2026 | https://conductscience.org/library/papers/42658373 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CTNNB1 | 1499 | PubTator's text mining | https://conductscience.org/library/genes/1499 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| MLH1 | 4292 | PubTator's text mining | https://conductscience.org/library/genes/4292 | NCBI Gene |
| MSD | 4434 | PubTator's text mining | https://conductscience.org/library/genes/4434 | NCBI Gene |
| MSH2 | 4436 | PubTator's text mining | https://conductscience.org/library/genes/4436 | NCBI Gene |
| MSH6 | 2956 | PubTator's text mining | https://conductscience.org/library/genes/2956 | NCBI Gene |
| PMS2 | 5395 | PubTator's text mining | https://conductscience.org/library/genes/5395 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Drugs3
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL11359 | ChEMBL |
| CARBOPLATIN | CHEMBL1351 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1351 | ChEMBL |
| PACLITAXEL | CHEMBL428647 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL428647 | ChEMBL |
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| ISRCTN | ISRCTN14387080 |
Source ISRCTN
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32749941
GET https://conductscience.org/api/papers/v1/32749941/authors?page=2